- Trial Phase
- Filed / PDUFA (Phase 3 completed)
- Time to Market
- PDUFA date is August 5, 2026. If approved, the vaccine could be available for the 2026/2027 Northern Hemisphere flu season. Regulatory submissions are also under review in Europe, Canada, and Australia, with potential approvals expected in 2026.
- Why 7/10
- The next hard, dated catalyst is the FDA PDUFA goal date of August 5, 2026 — roughly 5 weeks away — for mRNA-1010 (mFlusiva), Moderna's seasonal influenza vaccine for adults 50+. This is a binary regulatory decision on the company's most important near-term growth asset. The AdCom voted 9-0 in favor, strongly de-risking approval, but the PDUFA is still a high-impact event that will determine whether Moderna can launch its first non-COVID mRNA product.
Watch for the FDA decision by August 5, 2026. The unanimous 9-0 advisory committee vote on June 18 makes approval the base case, and the stock has already re-rated from a 52-week low of $22 to ~$71 on the expectation — so a positive decision may be partially priced in. Approval would unlock a new multi-billion-dollar TAM for Moderna beyond COVID; a surprise CRL would be a severe setback for the stock given how much of the 2026 rally is built on flu vaccine hopes.
Price Chart
Executive Summary
mRNA-1010 (brand name: mFlusiva) is Moderna's first non-COVID product to reach an FDA decision, and it is the single most important near-term catalyst for the stock. Two Phase 3 trials demonstrated superiority over standard-dose influenza vaccines in adults 50+, with results published in the NEJM. After a dramatic reversal — the FDA initially refused to file the BLA in February 2026, then reversed course — the agency's advisory committee voted unanimously (9-0) to recommend approval on June 18. The PDUFA goal date is August 5, 2026. The stock has rallied from a 52-week low of $22.28 to ~$71 on the flu vaccine narrative, though analyst consensus remains a Hold with a mean price target of $44.25 — meaning the stock has already overshot consensus expectations. Approval would open a major new revenue stream beyond COVID; rejection (a CRL) would be a severe blow to Moderna's post-pandemic growth story.
How It Works
mRNA-1010 is an mRNA-based seasonal influenza vaccine. Like Moderna's COVID vaccine, it uses messenger RNA to instruct the body's cells to produce hemagglutinin (HA) surface proteins from four influenza virus strains recommended by the WHO (two influenza A strains and two influenza B strains). This trains the immune system to recognize and fight the actual virus. The key advantage over traditional egg- or cell-based flu vaccines is speed of manufacturing (no eggs or cell culture needed) and potentially better immune responses.
Trial Status
Two pivotal Phase 3 trials completed with 43,808 total participants. Results published in the New England Journal of Medicine (May 7, 2026) showed mRNA-1010 was superior to standard-dose licensed vaccines for prevention of RT-PCR-confirmed influenza-like illness in adults 50+. The FDA's VRBPAC advisory committee voted 9-0 on June 18, 2026 that benefits outweigh risks. BLA is under FDA review with a PDUFA date of August 5, 2026.
The Two-Sided Case
Upcoming Catalysts
- August 5, 2026 — FDA PDUFA decision on mRNA-1010 (mFlusiva) for seasonal influenza
- Regulatory decisions in Europe (EMA), Canada, and Australia expected later in 2026
- Potential ACIP (CDC advisory committee) recommendation meeting if approved, determining vaccine reimbursement and guideline positioning for the 2026/2027 flu season
- Q2 2026 earnings call — Moderna's financial outlook and mRNA-1010 launch preparation commentary
Source Filing
The SEC filing that triggered this drug report: